Drug intelligence / Profile preview

DA-OTC-002

Development stage: Preclinical
Lead developer: Jupiter Wellness
Modality: Small Molecules
Administration: Topical

Overview

DA-OTC-002 is a topical small molecule drug under investigation as a cosmetic hair treatment. It is characterized as a combination of an alpha-1 adrenergic receptor agonist and a trace amine-associated receptor agonist. Its principal mechanism is presumed to stimulate hair growth or prevent hair loss by activating these adrenergic and trace amine pathways. The drug was developed by Applied Biology and has undergone prospective, institution-level, interventional, single-blinded, placebo-controlled clinical investigation for its effect as a topical cosmetic for hair[1].

Brand names: DA-OTC-002DA-OTC002DA-OTC 002
Other names: DA-OTC-002DA-OTC002DA-OTC 002

Targets

TAAR1 (Trace amine-associated receptor 1)ADRA1A (α1A)

Beyond the preview

Go deeper on DA-OTC-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-OTC-002.

Explore the full profile